Neurocrine's (NBIX) Data Deluge Reshapes A Familiar Growth Story
On August 12, Neurocrine Biosciences (NASDAQ:NBIX) published something unusual for a psychiatric drug: proof that patients feel the difference, not just that a clinician's scale says they moved less.







